RE:RE:RE:RE:Information Circularbeenthere, it wouldn't surprise me that the first few licencees may get a sweeter deal than those that follow, however, there are licensing formulas for each indication based on the potential revenue and/or exclusivity.
Regarding a buyout, yes, it's concerning to think that we might not get a good run in the market before that happens. However, it wouldn't surprise me if a bidding war ensued if any pharma did try to take us out.
Sniper